Originator
Theodrenaline,ZYF Pharm Chemical
Definition
ChEBI: Theodrenaline is an oxopurine.
Manufacturing Process
A solution of 27 g of ω-chloroacetopyrocatechol in 150 ml of ethyl alcohol is
added dropwise within 2 hours into a stirred and refluxed solution of 81 g of
7-(β-aminoethyl)theophylline in 200 ml of a 60% aqueous ethyl alcohol.
Following this, boiling is continued for another 3.5 hours while passing
through nitrogen, and the precipitated product is separated by suction
filtration, washed with water and dried. The product is suspended in alcohol,
admixed with alcoholic hydrochloric acid while heating until an acid reaction is
observed and subjected to suction filtration after cooling. Obtained in this
manner are 37 g of 7-[β-(β'-3,4-dihydroxyphenyl-β'-
oxoethylamino)ethyl]theophylline hydrochloride having a melting point of 246-
249°C. To obtain an analytically pure product, the hydrochloride is dissolved in
water and precipitated with acetone.
7.1 g of 7-[β-(β'-3,4-dihydroxyphenyl-β'-oxoethylamino)ethyl]theophylline
hydrochloride are dissolved in 500 ml of distilled water and hydrogenated at
48°C in the presence of 1 g of platinum oxide. When no further hydrogen is
absorbed after about 5 hours, the mixture is evaporated to dryness in vacuo.
Purification is effected by taking up in methyl alcohol and mixing with ethyl
acetate. Theodrenaline which has crystallized after several days is separated by suction
filtration and dried in a desiccator. A product having a melting point of 176-
178°C is obtained in amount of 6.1 g.
Therapeutic Function
Analeptic
Biological Activity
Theodrenaline is a cardiotonic agent that is also often mixed with cafedrine in a proportion to form Akrinor, which has blood pressure-lowering effects.
in vitro
Akrinor evokes a positive inotropic effect in human atrial trabeculae via stimulation of β-adrenoceptors (AR).
in vivo
Akrinor TM produces significant potentiation of FSK effects, conceivable by PDE-inhibition, only at very high, clinically irrelevant concentrations of 420 mg/L.
